Introduction/Background Survival benefit of the repeated intraperithoneal chemotherapy after surgery was demonstrated in GOG studied for ovarian cancer patients. However, catheter-related complications and accumulated toxicity made the procedure non-feasible. Recent randomized clinical trials OVHIPEC-1 and the Korean trial reported the positive effect on survival of HIPEC after the radical cytoreductive surgery (CRS) for ovarian cancer patients that were not eligible for primary CRS, but for interval CRS only.

Methodology The feasibility study (NCT03717610) started at October 2018 at the Department of Obstetrics and Gynecology, Academical hospital, Uppsala, Sweden. It comprises 10 patients with ovarian cancer relapse and macroscopically radical surgery outcome. HIPEC with cisplatin 90 mg/m² for 90 min in the hyperthermic phase 41–42°C is performed. Sodium thiosulfate infusion concomitant to the HIPEC treatment protects against the nephrotoxicity. Clinical variables, laboratory tests, EORTC questionnaires are evaluated. The study is performed under the regulations of the local IRB. Study endpoints are toxicity, tolerability, high-grade complications and quality of life after the macroscopically radical ovarian cancer relapse surgery followed by HIPEC.

Results We observed prolonged surgery time, one case of 3b (reoperation) 30-days morbidity, light to moderate nausea in 3 of 4 cases, no kidney toxicity and no neutropenia. The observations are case-wise related to the clinical parameters from the cohort of ovarian cancer relapse treated in 2009–2018. Table 1 summarizes the clinical and surgical observations.

Conclusion HIPEC is a feasible procedure, toxicities comprise mild gastrointestinal events, prolonged surgery time corresponds to the HIPEC procedure, no impact on the quality of life is observed.

Disclosure Nothing to disclose.